Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences (NBIX), has demonstrated a clear selling bias in his recent transactions, with $4.49 million in total sales outweighing $1.10 million in purchases across 35 reported trades. His activity has been exclusively concentrated in NBIX shares, with no transactions in other companies. The most significant recent sale occurred on February 13, 2026, when Lippoldt disposed of shares worth $667,517 through a derivative transaction (Code F), followed by additional dispositions totaling $139,511 and $135,167 the same day. This follows a pattern of consistent selling, including a $698,615 open-market sale (Code S) on December 8, 2025, and multiple smaller sales throughout early 2026.
Lippoldt’s transactions show a mix of open-market sales (Code S) and derivative dispositions (Code F), with the latter becoming more prominent in recent months. While some filings reflect minor acquisitions through equity awards (Code M), such as the $120,531 transaction on January 8, 2026, these have been substantially outweighed by his sales. The absence of any recent purchases suggests a continued reduction in his NBIX holdings, with the most recent activity—four sales in early 2026—reinforcing this trend. The filings indicate no new buying activity since at least early 2025, highlighting a prolonged period of net divestment.
AI-assisted summary